Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.59 |
| ▸ | MEN1 | O00255 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.59 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30122114 | 0.88 | SIRT1 (0.70) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL20446235 | 0.88 | SIRT1 (0.70) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL20446233 | 0.88 | SIRT1 (0.70) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL684655 | 0.87 | SIRT1 (0.70) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL684972 | 0.86 | MEN1 (0.59) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL684642 | 0.83 | KMT2A (0.73) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL684624 | 0.82 | SIRT1 (0.77) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL22179546 | 0.80 | PIK3CG (0.60) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL20587716 | 0.80 | PIK3CG (0.60) | SIRT1KMT2AMEN1MAPTLMNA | |
| SCHEMBL20587714 | 0.80 | PIK3CG (0.60) | SIRT1KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455394-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455394-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120021065-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021065-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, SOD3 | SIRT1 2400/4885KMT2A 1362/4885MEN1 536/4885 |
| US-20120021065-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, CYP4Z1 | SIRT1 1977/4885KMT2A 1224/4885MEN1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.